Trump Pushes Importation, Claims Success In Lowering Prices
Rally-style speech in Florida keeps rhetorical heat on biopharma – including a suggestion that industry may be behind impeachment – but the Administration also appears focused on promoting the idea that its drug pricing efforts have already worked.
You may also be interested in...
Allowing multi-regulator collaboration on oncology application assessment may run into pricing issues if Canada and Australia gain access to novel drugs before European countries, US FDA's Pazdur says.
Former drug pricing advisor John O’Brien discusses next steps for Administration policies around importation and international reference pricing during a speech to the Academy of Managed Care Pharmacy.
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.